Prognostic Significance of High-Grade Prostatic Intraepithelial Neoplasia (HGPIN): Risk of Prostatic Cancer on Repeat Biopsies

The risk for cancer after HGPIN diagnosis (21.5%) was not higher than the risk reported after BPT diagnosis (23.0%). PSA and HGPIN focality at biopsy do not enhance cancer predictivity. Patients with a HGPIN diagnosis do not seem to need any different follow-up rebiopsy strategy than patients with a BPT diagnosis.